Role of advanced glycation end products and their receptors in development of diabetic neuropathy

被引:189
|
作者
Wada, R [1 ]
Yagihashi, S [1 ]
机构
[1] Hirosaki Univ, Sch Med, Dept Pathol, Hirosaki, Aomori 0368562, Japan
关键词
advanced glycation end product; receptor; diabetes; neuropathy; microangiopathy; ALDOSE REDUCTASE INHIBITOR; OXIDE SYNTHASE ACTIVITY; PERIPHERAL-NERVE; ENDOTHELIAL-CELLS; NITRIC-OXIDE; BINDING-PROTEINS; RATS; AMINOGUANIDINE; GLYCOSYLATION; EXPRESSION;
D O I
10.1196/annals.1338.067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetic neuropathy is a life-threatening complication involving both peripheral and autonomic nerves. The hyperglycemia-induced polyol pathway as well as enhanced oxidative stress are among the factors implicated in the pathogenesis of diabetic neuropathy. Their effects are possibly exerted by direct nerve tissue damage or mediated by endothelial injury or vascular dysfunction. Formation of advanced glycation end product (AGE) is another important candidate for the cause of peripheral neuropathy. Indeed, the levels of AGEs were increased in the serum and also in the peripheral nerves obtained from diabetic patients. Structural and functional proteins of those nerves are also glyeated, resulting in impaired nerve function and characteristic pathologic alterations. In addition, interaction between AGEs and their receptors induce biological effects on the target tissues for diabetic complications. In the peripheral nerve, the receptor for AGE (RAGE) is expressed in endothelial and Schwann cells. It is thus anticipated that interactions between AGEs and RAGE facilitate endoneural vascular dysfunction, leading to microangiopathy in the peripheral nerve. The roles of these mechanisms, in particular on the molecular mechanisms of AGE-RAGE interactions in the development of diabetic neuropathy are largely still speculative and yet to be explored.
引用
收藏
页码:598 / 604
页数:7
相关论文
共 50 条
  • [1] Role of advanced glycation end products in diabetic neuropathy
    Sugimoto, Kazuhiro
    Yasujima, Minoru
    Yagihashi, Soroku
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 953 - 961
  • [2] Advanced glycation end products, their receptors and diabetic angiopathy
    Wautier, JL
    Guillausseau, PJ
    DIABETES & METABOLISM, 2001, 27 (05) : 535 - 542
  • [3] Advanced Glycation End-Products and Diabetic Neuropathy of the Retina
    Oshitari, Toshiyuki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [4] Role of advanced glycation end products in diabetic nephropathy
    Forbes, JM
    Cooper, ME
    Oldfield, MD
    Thomas, MC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : S254 - S258
  • [5] Expression of advanced glycation end products and their receptors in diabetic periodontitis patients
    Thomas, Julie Toby
    Joseph, Betsy
    Sorsa, Timo
    Mauramo, Matti
    Anil, Sukumaran
    Waltimo, Tuomas
    ORAL DISEASES, 2024, 30 (05) : 2784 - 2796
  • [6] The Role of Advanced Glycation End Products in Diabetic Vascular Complications
    Rhee, Sang Youl
    Kim, Young Seol
    DIABETES & METABOLISM JOURNAL, 2018, 42 (03) : 188 - 195
  • [7] THE ROLE OF ADVANCED GLYCATION END PRODUCTS IN PATOGENESIS OF DIABETIC NEPHROPATHY
    Gavrilova, Alina O.
    Severina, Anastasia S.
    Shamhalova, Minara S.
    Shestakova, Marina, V
    DIABETES MELLITUS, 2021, 24 (05): : 461 - 469
  • [8] Advanced glycation end products: role in pathology of diabetic cardiomyopathy
    Bodiga, Vijaya Lakshmi
    Eda, Sasidhar Reddy
    Bodiga, Sreedhar
    HEART FAILURE REVIEWS, 2014, 19 (01) : 49 - 63
  • [9] Advanced glycation end products: role in pathology of diabetic cardiomyopathy
    Vijaya Lakshmi Bodiga
    Sasidhar Reddy Eda
    Sreedhar Bodiga
    Heart Failure Reviews, 2014, 19 : 49 - 63
  • [10] The role of advanced glycation end products in the development of atherosclerosis
    Peppa M.
    Uribarri J.
    Vlassara H.
    Current Diabetes Reports, 2004, 4 (1) : 31 - 36